Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing cardiovascular events in patients with chronic ischemic heart disease.Lp-PLA2 is an enzyme found in the blood andatherosclerotic plaques and high levels are associated with an increased risk of cardiovascular events.Direct inhibition of this enzyme with proinflammatory Daraplabid may benefit these patients along with other standard medication.15828 patients with chronic coronary disease were randomized to receive Daraplabid160 mg / day or placebo with a follow up period of 3.7 years.
The primary end point was a composite of death, myocardial infarction and stroke and the secondary end point included major coronary events and total coronary events.Over 90 % of patients were receiving aspirin and statins.No differences between groups in the incidence of the primary end point (placebo group 10.4 % versus Daraplabid group 9.7 %, P = 0.199) were observed.
Conclusion
Using Daraplabid showed no benefit in terms of the incidence of death, heart attack or stroke.
Harvey White
2014-03-31
Original title: Effect of Inhibition of Lipoprotein-Associated Phospholipase A2 with Darapladib on Ischemic Events in Patients with Chronic Coronary Heart Disease: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIbTherapY) Trial.
